Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Zainab Fuad"'
Publikováno v:
International Journal of Biomedicine, Vol 14, Iss 3, Pp 379-385 (2024)
Background: In 2023, the FDA approved two emerging cell-based gene therapies for the treatment of severe sickle cell disease (SCD): Casgevy and Lyfgenia. Casgevy utilizes the newer CRISPR/Cas9 technology, while Lyfgenia relies on a Lentiviral vector.
Externí odkaz:
https://doaj.org/article/74153cb9e4c54ea6ac3322fa27a33ab4
